All articles by Vidya Sagar Maddela
Vidya Sagar Maddela
Roche unveils promising Phase 1/2 results for NXT007 in haemophilia A
Developed by Chugai, part of the Roche Group, NXT007 is an investigational drug that promotes haemostatic normalisation in patients without factor VIII inhibitors and builds on Hemlibra’s framework.
Argenx secures EC approval for Vyvgart to treat CIDP
The EC approval allows patients previously treated with corticosteroids or immunoglobulins to receive Vyvgart as a subcutaneous injection (SC) monotherapy that can be administered by patients, caregivers, or healthcare professionals.
GSK’s application for expanded use of Arexvy accepted in Japan
The application seeks expanded use of the vaccine, which was previously approved for adults aged 60 and older and those aged 50 and older at increased risk of RSV, to include adults aged 18-49 at increased risk of severe RSV
Incyte secures FDA approval for Monjuvi combination to treat FL
The FDA approval follows the inMIND trial, a randomised, double-blind, placebo-controlled Phase 3 study, evaluating the efficacy and safety of Monjuvi combined with rituximab and lenalidomide.
Actio Biosciences secures $66m funding for genetics-driven drugs
The funding aims to advance Actio’s genetics-driven pipeline of small-molecule therapeutics targeting both rare and common diseases, including its lead programmes, ABS-1230 and ABS-0871.
ADVANZ PHARMA acquires Testoviron rights from Bayer in Europe and parts of LATAM, MEA, and APAC
ADVANZ PHARMA will provide access to the medicine through its European operations and global partner network
LCRF, Boehringer Ingelheim collaborate on HER2 lung cancer research
The $2.25m research initiative includes two funding mechanisms, the Team Science Award and the Early Career Investigator Award, focused on understanding and treating lung cancers with HER2 mutations.
Lilly to acquire Verve Therapeutics to advance gene editing treatments
The acquisition aims to advance Verve’s advanced one-time treatments for individuals with high cardiovascular risk, including atherosclerotic cardiovascular disease (ASCVD).
Celltrio Secures $15 Million Financial Investment to Accelerate Global Expansion in Cell Culturing and Cell & Gene Therapy Automation
Celltrio designs and manufactures scalable cell culture automation platforms that integrate seamlessly into R&D and GMP environments
Teva, Fosun Pharma partner to develop anti-PD1-IL2 therapy TEV-56278
The collaboration aims to enhance the clinical data generation for TEV-56278, an investigational anti-PD1-IL2 therapy created using Teva’s in-house attenukine technology.